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INTERACTIONS BETWEEN POLYMER NANOPARTICLES AND  
BLOOD PLASMA APPLIED TO DRUG DELIVERY SYSTEMS 
by 
Mark Stephen Bannon 
Targeted nanoparticle drug delivery has the potential to replace current forms of cancer 
therapy with previously unparalleled efficiency. Upon introduction into the human body, 
nanoparticles exhibit a substantial increase in diameter due to a biomolecular corona 
formation caused by interactions between blood plasma proteins and the nanoparticles. 
These interactions must be analyzed and understood for targeted delivery to reach its 
potential in both feasibility and efficiency. 
To study the formation of the protein corona, polystyrene nanoparticles were 
incubated in vitro in goat blood plasma for 10-minute intervals, diluted to different degrees 
and then measured to obtain the hydrodynamic diameter of said particles. This was done 
using Nanoparticle Tracking Analysis (NTA) with the Malvern Nanosight NS300’s more 
reliable fluorescent capabilities as opposed to the more commonly used Dynamic Light 
Scattering Particle Size Analysis (DLS). 
The results of this experiment showed that the size of the nanoparticles being 
incubated in blood plasma increases as the solutions become more dilute. These results 
were then plotted and characterized by linear regression in order to distinguish between the 
hard and soft coronas. The experiment also proved that NTA is a more reliable method for 
measuring nanoparticles in blood plasma than the commonly used DLS. These findings 
have major implications towards targeted nanoparticle drug delivery and will ultimately 
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This dissertation’s objective is to quantify the interactions between drug delivery particles 
and the biological milieu in which they are working in, in this case blood plasma. For the 
dilution experiment used, nanoparticles were incubated in different goat blood plasma 
solutions and then diluted with saline. Said plasma was diluted incrementally for each 
iteration. Analysis of incubated particle size was done using the Malvern Nanosight 
NS300, based upon a comparison of results attained using both nanoparticle tracking 
analysis of the Malvern Nanosight NS300 and dynamic light scattering of the Malvern 
Zetasizer Nano ZS. The results of said dilution experiment were plotted against the 
logarithm of the percentage of plasma in each dilution and regressed linearly using Minitab. 
Statistical analysis was then completed on both the plotted data and the linearly regressed 
equations to determine the statistical significance of said data. 
 
1.2 Background Information 
Nanoparticle drug delivery systems provide a straight-lined method of delivering necessary 
therapy to parts of the body that require it. This technology has the potential to replace 
harmful techniques, such as systemic chemotherapy, to treat cancer patients, as it would 
provide a less harmful and more effective cancer treatment than current techniques can 
offer. An example of a nanoparticle used for drug delivery within the human body can be 






Figure 1.1 Drug Delivery Nanoparticle Diagram 
 
 The blue shell of the nanoparticle represents the actual material comprising the 
nanoparticle, in the specific case described in this paper it would be a polymer such as 
Polystyrene or PLGA. Other options for this material for drug delivery use include gold or 
lipid nanoparticles. The green circle within the nanoparticle represents the encapsulated 
drug meant to be delivered to specific targeted areas within the body. Finally, the orange 
arrows represent targeting ligands on the surface of the nanoparticles. These ligands can 
locate and bond to parts of the body in need of the encapsulated drug, such as tumors. This 
binding allows for the nanoparticle to release its encapsulated drug to the intended parts of 
the body, completing the drug delivery. 
Despite the untapped potential of these systems, there are issues standing between 
the design and implementation of nanoparticle drug delivery. One of these issues is the 
interactions that occur between nanoparticles and the blood of the patient receiving therapy. 
Upon incubation, these nanoparticles demonstrate an affinity to certain compounds that are 





of these blood plasma compounds surrounding the nanoparticles, which can cause either a 
simple size increase or a large aggregation of particles moving through the body [13]. 
Upon a nanoparticle’s entrance into the bloodstream, one will observe an increase 
in the particle’s hydrodynamic diameter. As the nanoparticle encounters proteins located 
in the blood plasma, attractions form between the nanoparticle’s surface and the proteins, 
causing the proteins to bind onto the nanoparticle. Unfortunately, these coronas are 
extremely complex, resulting from possible interactions with the thousands of different 
proteins at differing concentrations present in the blood. In turn, the protein corona of 
nanoparticles can differ from patient to patient, incubation to incubation within the same 
patient and even from nanoparticle to nanoparticle during the same incubation. 
The protein corona can be separated into two different phases: the hard corona and 
the soft corona. The current model of a protein corona shows that the hard corona is 
comprised of proteins that are directly bound to the nanoparticle surface, acting as an outer 
shell around the particle itself [13]. The main method of this protein adsorption is entropy-
driven binding, which occurs upon the release of water molecules from the surface of the 
nanoparticle. The second part of the corona, the soft corona, comprises of proteins that 
loosely bind to either the nanoparticle’s surface or the hard corona proteins themselves, 
creating protein-protein interactions [13]. The overall development of a protein corona onto 












Figure 1.2 Development of a Protein Corona onto a Nanoparticle 
 
Figure 1.2 represents a protein corona formed upon incubation of one of the 
nanoparticles described by Figure 1.1. The red and yellow shapes represent different 
proteins contributing to the hard and soft corona; however, it is important to remember that 
both layers can be made of a mixture of different proteins. Figure 1.2 shows that the orange 
targeting ligands are no longer visible on the surface of the particle. The soft protein corona 
primarily contributes to the corona’s overall masking effect, which chemically changes the 
composition of the particle within its incubated biological milieu. This masking effect 
blocks the targeting ligands from locating and binding to locations in the body that require 
the drug encapsulated within the nanoparticle [19]. This diagram shows the negative effects 
of protein corona, which can lead to the failure of drug delivery systems. 
The composition of the protein corona is determined from many variables, which 
include (but are not limited to) nanoparticle size, shape, composition, surface charge, 
hydrophobicity/hydrophilicity, etc. Another very important variable affecting the size and 
composition of the protein corona is the surface chemistry of the nanoparticle. There are 





effective methods is through PEGylation. PEGylation refers to adding polyethylene glycol 
chains to the surface of the nanoparticles, which makes the particle much more hydrophilic 
and therefore less prone to aggregation and large protein coronas [13].  
While the variables previously discussed contribute heavily to the formation of 
protein coronas on select nanoparticles, the corona composition during incubation is 
governed by a law known as Vroman’s effect. This law states that the most abundant 
proteins are adsorbed onto the nanoparticle surface upon initial incubation, however as 
time goes on proteins with higher affinity to the nanoparticles will replace the initially 
adsorbed proteins [13]. This presents an even bigger issue, as it Vroman’s effect dictates 
that the protein corona is changing over time, with new proteins constantly adsorbing onto 
and desorbing from the surface of the nanoparticle. However, it does let us know that 
proteins such as albumin, fibrinogen, apolipoproteins and certain immunoglobulins 
(among the most abundant proteins in the blood plasma) should always be present on the 
protein corona in some capacity [19].  
While Vroman’s effect is hard enough to predict, the nanoparticles being incubated 
in blood plasma will constantly be in motion, which the conducted experiments do not 
account for. When nanoparticles are incubated in a dynamic environment, the effect of 
Brownian motion must be considered. Brownian motion is based upon random movement 
of particles in suspension, which causes the nanoparticle surface adsorption of a plasma 
protein to be dependent upon the probability of that specific protein species to encounter 
the nanoparticle. By this logic, larger proteins and proteins in high abundance are more 





up a larger volume within the bloodstream and are more likely to collide with the 
nanoparticles [13]. Brownian motion will be discussed in greater detail in Chapter 2 
 The masking effect that accompanies these interactions between the nanoparticles 
and blood plasma components ultimately causes drug delivery through these nanoparticle 
systems to become a near impossible task. In order to efficiently implement nanoparticle 
drug delivery to its full potential, one must first understand the interactions between the 
nanoparticles and the plasma components. For this reason, it is extremely important to 
understand not only how Vroman’s effect collaborates with Brownian motion, but also how 
to control the two laws. 
 The plasma being used for this experiment is derived from goat blood. While the 
eventual drug delivery systems will be applied to human test subjects, goat plasma serves 
as an effective and safer substitute. A study done by Morris et al compared human blood 









Figure 1.3 Comparison between Human and Goat Blood Plasma Using Zone Electropho-
resis 
Source: Morris, Bede, and F. C. Courtice. “The Protein And Lipid Composition Of The Plasma Of Different 
Animal Species Determined By Zone Electrophoresis And Chemical Analysis.” Quarterly Journal of 






The above graphs display the similarities between goat and human blood plasma. 
The large peak on the right indicates the relative amount of the plasma protein albumin in 
both types of blood: the results clearly show that goat blood plasma contains more. Goat 
blood plasma also contains higher concentrations of gamma globulin and fibrinogen, two 
proteins very abundant in human blood plasma. Goat blood plasma also contains beta and 
alpha globulin fractions. The major difference comes with the lipid composition. Zone 
electrophoresis separated lipids available in human plasma into three distinct categories, 
while goat blood plasma’s lipids were only separated into two categories. Despite this 
minor difference, Morris confirms that it is acceptable to use goat blood plasma as a 




















METHOD COMPARISON FOR NANOPARTICLE SIZE MEASUREMENT 
 
2.1 Dynamic Light Scattering 
Dynamic light scattering is the most common technique used to size nanoparticles in 
suspensions [19]. When in a suspension such as blood plasma, nanoparticle movement 
adheres to the laws of Brownian motion, which is used to describe the randomized 
movement of microscopic particles in a fluid. This erratic movement is usually a result of 
constant bombardment by molecules of the surrounding medium, which in these 
experiments is blood plasma [6]. Because these particles are so small, and their randomized 
location makes it impossible to predict their locations, it is quite difficult to see, and 
therefore size, these particles. DLS transmits waves of light through a suspension with 
microscopic particles. The particles will scatter this transmitted light, which allows for their 
state of motion to be measured [10].  
 DLS uses the Stokes-Einstein equation to calculate a particle’s hydrodynamic 
diameter. The Stokes-Einstein equation can be shown in Figure 2.1: 
 
Figure 2.1 Stokes-Einstein Equation 







In the above equation, “k” represents Boltzmann’s constant, “T” represents absolute 
temperature, and “Ƞ” represents the dynamic viscosity of the suspension. DLS measures 
the parameter “D”, which is the translational diffusion coefficient. This parameter 
describes the speed of the Brownian motion [6]. Because the other parameters are usually 
known, it becomes easy to measure “d(H)”, which represents the hydrodynamic diameter 
of particles in suspension. Hydrodynamic refers to “how a particle diffuses within a fluid”. 
Because it is impossible to know the exact shape of the particles through DLS, the 
hydrodynamic diameter represents the diameter of a sphere that has the same translation 
diffusion coefficient as the particle [6]. 
DLS calculates this hydrodynamic diameter using the measured intensity of light 
scattered from particles in suspension. This intensity is then fit to a correlation curve, where 
the correctness of fit is determined for the measured data. The correlation curve will always 
be used to calculate the perceived hydrodynamic diameters of the particles, however the 
accuracy of said curve depends upon the quality of the data measured from a sample [6].  
While dynamic light scattering is a useful technique for nanoparticle sizing, it has 
a significant drawback that prevents it from being reliable for sizing polymer nanoparticles 
in blood plasma. Blood plasma has an innumerable amount of proteins in it, which just as 
readily scatter light as the polymer nanoparticles being used in drug delivery solutions. The 
problem is that as plasma is introduced into the solution, a large amount of plasma proteins 
enters the system, which can create variation in the measurements in two ways. One, 
variation in the sizes of particles present in suspension will affect the correlation curve and 
produce a less accurate fit of size data. Second, as there becomes a greater concentration 





in the solution, then DLS will be measuring the size of those more abundant proteins. This 
makes it nearly impossible to measure the size of nanoparticles in solvents mainly 
comprised of blood plasma. To understand how these particles behave in the blood stream, 
it is important to be able to measure their size in pure blood plasma. While DLS is a more 
common and perfected technique for particle sizing, its ambiguity in nanoparticle 
selectivity provides a problem in implementation.  
 
2.2 Nanoparticle Tracking Analysis 
The idea of nanoparticle tracking analysis is similar to that of dynamic light scattering, 
where a laser is sent through a microfluidic device containing a suspension of particles in 
blood plasma. It also uses the Stokes-Einstein equation to calculate hydrodynamic 
diameters of particles. As opposed to DLS, NTA analyzes the individual sizes of 
nanoparticles by measuring the translational diffusion coefficient of each nanoparticle in 
suspension. The mode size of particles present in the suspension will then be reported, 
according to the concentration of the particles in suspension per milliliter [14]. 
As discussed in the previous section, DLS has trouble differentiating between the 
proteins found in blood plasma and the nanoparticles in suspension. NTA has the 
convenience of customized lasers and fluorescent filters, which send out specific 
wavelengths of light that can excite the fluorescently tagged nanoparticles. The fluorescent 
light from the fluorescently tagged particles has a higher wavelength than the laser used to 
excite them; for example, if a 488-nanometer laser was sent into the suspension, the 
fluorescent light from the fluorescent yellow-green tagged nanoparticles would be over 





found in blood plasma, will only scatter light at the same wavelength of the laser.  If a 500 
nm fluorescent filter is being used, the scattered light at 488 nm will be blocked and only 
the fluorescent light from the nanoparticles will be analyzed [14]. 
Essentially, the fluorescent capabilities of NTA allow users to measure only their 
targeted particles in suspensions while blocking the scattered light from unwanted 
particles. This unwanted scattered light is also referred to as “noise”. This enhanced 
measuring selectivity makes NTA a theoretically superior method of sizing drug delivery 
nanoparticles in suspensions containing blood plasma. In addition, the fluorescent 
capabilities of NTA could theoretically allow a user to determine the size of particles in 
undiluted blood plasma, which is not possible in DLS. The theoretical capabilities of NTA 
make it a more suitable technique for evaluating polymer drug delivery nanoparticles in 
blood plasma than DLS [14]. 
 
2.3 Methods and Materials 
Whole goat blood with Alsevers solution was purchased from Lampire Biological 
Laboratories. Alsevers solution served as the anticoagulant in the blood and refers to an 
isotonic salt solution. The specific blood purchased comprised of 50% Alsevers solution 
and 50% whole goat blood. Whole goat blood with Alsevers solution was chosen to match 
the same type of blood used in earlier experiments so comparisons could be made between 
the two samples. The blood was centrifuged for one hour, after which the resulting 
supernatant was removed and then centrifuged for another hour. This process was repeated 





Plasma accounts for about 55% of whole blood, and therefore after centrifugation 
the resultant solution is about 35.50% plasma and 64.50% isotonic salt solution, making 
the highest attainable percentage of plasma in dilution, which is represented by dilution 0, 
35.50% [4] [6] [20] [21] [24]. Because of the heavy dilution, the mixture of goat plasma 
and Alsevers will be referred to as “plasma solution”. 
The polystyrene particles were incubated in various amounts of plasma for 10 
separate dilutions. Each dilution contains 10 microliters of polystyrene nanoparticle 
solution (made of 100 microliters of stock yellow-green fluorescently-tagged polystyrene 
nanoparticle solution diluted with 900 microliters of saline solution) in 1000 microliters of 
a saline solution and plasma mixture. Dilution 0 contained 1000 microliters of plasma 
solution, with the amount of plasma in solution incrementally halved until dilution 9, the 
final dilution, contained 1.95 microliters of plasma solution and 998.05 microliters of saline 
solution. Table 2.1 summarizes each dilution, describing the amount of plasma and isotonic 
salt solution (Alsevers and saline) in each solvent dilution. The percentage of plasma 



























Saline in  
Final Dilution 
(µL) 
Dilution 0 1000.00 35.50% 355.00 645.00 
Dilution 1 500.00 17.75% 177.50 822.50 
Dilution 2 250.00 8.88% 88.75 911.25 
Dilution 3 125.00 4.44% 44.38 955.62 
Dilution 4 62.50 2.22% 22.19 977.81 
Dilution 5 31.25 1.11% 11.09 988.91 
Dilution 6 15.63 0.55% 5.55 994.45 
Dilution 7 7.81 0.28% 2.77 997.23 
Dilution 8 3.91 0.14% 1.39 998.61 
Dilution 9 1.95 0.07% 0.69 999.31 
 
Each particle suspension was vortexed for 10 seconds, and then placed in a water 
bath at 37°C for 10 minutes, which simulated environmental conditions of the human body. 
After this 10 minute incubation period, saline was added to the solution until it had a 
volume of 1000 microliters, or 1 milliliter. The saline solution was previously heated to 
37°C for the same amount of time as the particle suspension to ensure that a constant 
temperature was maintained. For this specific experiment, dilutions 6 through 9 as well as 
nanoparticles measured in pure saline solution were prepared and analyzed using DLS and 
NTA. For the solution of pure saline, 10 microliters of polystyrene nanoparticle solution 





First, for DLS, the solution was loaded into a disposable plastic cuvette by means 
of transfer pipette. This plastic cuvette was then loaded into a Malvern Zetasizer Nano ZS, 
of which a schematic can be found in Figure A.1. A standard operating procedure was 
created in which 3 sets of 12 measurements were taken to analyze the size of any particles 
in solution, each measurement lasting 5 seconds. For each set, the results of the 12 
measurements were averaged together to determine the most commonly recurring peak 
sizes, or modes, of the hydrodynamic diameter data analyzed. For each dilution, the peak 
with the highest intensity, or the most commonly recorded peak size, was taken and 
averaged together to retrieve one overall dilution peak size. The full summary of analyzed 
data from the DLS can be found in Table A.1. 
In the case of NTA, the respective dilutions were loaded into the Nanosight NS300 
and pumped continuously through the microfluidic viewing device. The syringe pump was 
set to a flow rate of 100, which is measured using an arbitrary unit interpreted by the 
Nanosight NS300. This flow rate resulted in particles crossing the viewing area in five to 
ten seconds, the recommended time for particle analysis by NTA. The inner chamber of 
the Nanosight was then set to 37°C to maintain solution temperature throughout the 
experiments. This temperature mimics the temperature within the human body, allowing 
for the system to simulate the environment that the nanoparticles would experience in the 
body with as much accuracy as possible. The solution was analyzed using a 488-nanometer 
laser and a 500-nanometer fluorescent filter. A schematic of the Nanosight NS300 can be 
found in Figure C.1 
Sizing was completed by recording 10 one-minute videos of the particles in 





repeated three times for each of the ten diliutions until there were over 20 reliable video 
analyses. To be considered reliable, each solution had to have a concentration of at least 
1 × 108 particles per mL and not exceed minor vibration within the sample run time. If the 
sample was deemed acceptable, the mode hydrodynamic diameter of every fluorescently 
tagged particle was then calculated by the Stokes-Einstein equation (see Figure 2.1). The 
generalized particle size of each particle in solution was then determined by the mode of 
the calculated diameters from the Nanosight NS300’s analyzing capabilities.  
Finally, referring to Figure 2.1, the Stokes-Einstein equation takes the dynamic 
viscosity of the solvent being used into effect. Because each dilution’s viscosity is different, 
kinematic viscosity measurements had to be individually performed on each of the ten 
dilutions using a glass kinematic viscometer and then converted into dynamic viscosity. 
This can theoretically be done by multiplying the kinematic viscosity of a solution by the 
solution’s density, which was measured for each dilution used. The viscosity of each 
separate dilution was measured and taken into account to achieve accurate results, which 
is further discussed in Appendix B. 
 
2.4 Results 
The experiments explained in Section 2.3 resulted in measured hydrodynamic diameters of 
nanoparticles after incubation in various plasma dilution. This data is summarized in Tables 






Figure 2.2 Plotted Hydrodynamic Diameters of Polystyrene Nanoparticles After 
Incubation in Various Dilutions of Blood Plasma and Saline Solution 
 
Figure 2.2 shows the vast differences between the measurements taken by the two 
systems, where experiments were performed on dilutions 6 through 9. The asterisks next 
to the data points indicate that data quality used to create said points on the graph was too 
poor for an accurate result using the correlation function of DLS. Each plotted point 
represents the average of the mode hydrodynamic particle diameters for each individual 
measurement in DLS and NTA. 
Firstly, the standard error of each measurement using DLS is much greater than that 
of the NTA NS300. This is made visually apparent by the graph; however, as seen in Tables 
A.1 and C.1, the error produced by the Nanosight NS300 is in between 1 and 4 nanometers, 





error boasted by the Nanosight NS300 makes it a superior instrument, and as these 
experiments deal with extremely small size difference, it would create more reliant results 
than DLS. 
In order to accurately assess the results of these two methods, a comparison of the 
development of the results must be done. Figures 2.3 and 2.4 shows a comparison between 
the hydrodynamic diameters visually plotted by both DLS and NTA, respectively. 
 
 
Figure 2.3 Intensity Plotted Against Size Data Calculated by DLS in the Malvern Zetasizer 
Nano ZS Assessed According to the Goodness of Fit Shown by the Expert Advice Tab for 






Figure 2.4 Nanoparticle Concentration Plotted Against Size Data Calculated by NTA in 
the Nanosight NS300 for Saline, Dilution 0 
 
 Figure 2.3 shows the results of an individual DLS measurement characterized by 
the intensity of scattered light from particles in suspension plotted against their sizes on a 
semi log plot. Figure 2.4 shows the results of an individual NTA measurement 
characterized by the concentration of particles in suspension, also plotted against their sizes 
on a semi log plot. Both results are for particles incubated in pure saline. 
 Clearly, according to the expert advice tab for DLS’s measurement of particles in 
pure saline, the “data meets quality criteria”, meaning that it is accurate enough to calculate 
the size of the nanoparticles in suspension correctly. Therefore, the 207.90 nanometer size 
of the particles can be considered an accurate measurement. This is also comparable to the 






these two methods are analyzing size in different ways (NTA by number and DLS by 
intensity), they are not expected to produce exactly similar hydrodynamic diameters. 
Based on these results, both methods measure accurate hydrodynamic diameters of 
nanoparticles with limited error in a suspension of pure saline; however, the peak width of 
the Nanosight NS300’s data is clearly much smaller than the peak width of the Malvern 
Nanosight NS300’s data. This peak width is another testament to the accuracy of the 
Nanosight NS300 in saline size measurements, as the thinner peak represents less variable 
size measurements in each device. This trend of the Nanosight NS300’s thinner peaks will 
continue throughout the dilutions. 
Figures 2.5 and 2.6 represent the result of nanoparticle incubation in Dilution 8, 








Figure 2.5 Intensity Plotted Against Size Data Calculated by DLS in the Malvern Zetasizer 
Nano ZS Assessed According to the Goodness of Fit Shown by the Expert Advice Tab for 






Figure 2.6 Nanoparticle Concentration Plotted Against Size Data Calculated by NTA in 
the Nanosight NS300 for Plasma, Dilution 8 
 
 Once again, Figure 2.5 and 2.6 represent the results of two individual runs of 
Dilution 8 on the Nanosight NS300 and the Malvern Zetasizer. Unlike Figure 2.3, the 
Expert Advice reports the data quality as “too poor for cumulant analysis”, meaning that 
the correlation function used to size the data had too much error to accurately measure the 
hydrodynamic diameters using DLS. This is because there was too much variation in 
scattered light within the data, which one can only assume to be resulting from the addition 
of plasma and its inherent plasma proteins. Because the data quality is considered poor, the 
measured hydrodynamic diameter of 250.60 cannot be considered an accurate 





nm. The addition of plasma could lead one to assume that these two peaks represent 
different components within the plasma, most likely plasma proteins.  
 The peak of the NTA is still extremely defined, with no other peaks even coming 
close to the high concentration of the peak representing 278 nm. There is obviously a much 
larger difference between the results from DLS and NTA, and the poor quality of the DLS 
correlation fit leads users to consider the NTA’s measurement of 278 nm to be more 
accurate. Once again, the Nanosight NS300’s plotted data has a much narrower peak than 
the Zetasizer ZS’s. Obviously, as plasma is added to the incubating solution, there is a 
decrease in accuracy and reliability in results from DLS. Figures 2.7 and 2.8 show DLS 
and NTA data, respectively, for Dilution 6.  
 
 
Figure 2.7 Intensity Plotted Against Size Data Calculated by DLS in the Malvern Zetasizer 
Nano ZS Assessed According to the Goodness of Fit Shown by the Expert Advice Tab for 






Figure 2.8 Nanoparticle Concentration Plotted Against Size Data calculated by NTA in 
the Nanosight NS 300 for Plasma, Dilution 6 
 
Once again, Figure 2.7 and 2.8 represent the results of two individual runs of 
Dilution 6 on the Nanosight NS300 and the Malvern Zetasizer. The Expert Advice reports 
the data quality as “too poor for cumulant analysis” for Dilution 6, meaning that the 
correlation function used to size the data had too much error to accurately measure the 
hydrodynamic diameters using DLS. Because the data quality is considered poor, the 
measured hydrodynamic diameter of 232.60 nm cannot be considered an accurate 
measurement. It is also important to note that this size is smaller than that calculated by 





less dilute. It is safe to assume that the fit of the correlation function in the DLS 
measurement becomes poorer as more plasma is present in incubation and that this trend 
does not accurately reflect the real trend followed by incubated nanoparticles. The other 
peaks from Figure 2.5 are present in Figure 2.7 as well, and have increased in intensity, 
with the peak of 20.11 nm becoming comparable to the peak of 232.60. This also advocates 
the lower quality of Dilution 6’s data as opposed to Dilution 8’s in the Zetasizer ZS. 
 The peak of the NTA is still extremely defined, with no other peaks even coming 
close to the high concentration of that representing the 293 nm particles. Once again, 
conversely to DLS data, the size of the nanoparticles is increasing as the dilutions become 
less dilute. There is obviously a much larger difference between the results from DLS and 
NTA, and the poor quality of the DLS correlation fit leads users to consider the NTA size 
of 293 nm more accurate. The Nanosight NS300’s plotted data still has a much narrower 
peak than the Zetasizer ZS’s. As the solutions become less dilute, there is a decrease in 
accuracy and reliability in results from DLS. 
Obviously, one of these methods is providing flawed measurements of nanoparticle 
sizes in blood plasma. In theoretical terms, one would be inclined to claim that DLS 
presents flawed measurements as the percentage of plasma in dilution increases, which is 
supported by the poor quality of data used in the correlation function of the Zetasizer ZS’s 





Figure 2.9 Diagram of Nanoparticles in Blood Plasma 
 
Figure 2.9 represents a suspension of fluorescently tagged nanoparticles in blood 
plasma, much like the ones used in these experiments. The red, translucent background 
represents the blood plasma while the abundant, small red and yellow circular shapes 
represent plasma proteins within the plasma. The bright yellow fluorescently tagged 
polystyrene nanoparticles can still be clearly seen, however it would be impossible to 
measure the size of these nanoparticles due to the plasma proteins surrounding them. DLS 
shares this problem. There are thousands of different proteins in blood plasma, meaning 
that even if the different scattered light did not affect the quality of the data, the scattered 
light from the plasma proteins would be measured due to the higher concentration of 
proteins in solution. This can be compared to the fluorescent capabilities of the Nanosight 





Figure 2.10 Fluorescently Tagged Nanoparticles in Plasma Viewed through Fluorescent 
Filter 
 
 Figure 2.8 shows scattered light from fluorescently tagged nanoparticles viewed on 
the Nanosight NS300. Using the proper combination of lasers and fluorescent filters, the 
scattered light from the plasma proteins is not analyzed by the NS300, and only the 
fluorescent light from the fluorescently tagged nanoparticles is analyzed. Figure 2.10 still 
shows the outline of the protein corona formed onto the fluorescently tagged nanoparticles. 
Even though the light scattered by the protein corona is blocked by the filter, it’s existence 
still affects how the nanoparticles move through the suspension and will therefore affect 
the measured translational diffusion coefficients of the nanoparticles. 
 The poor data quality displayed in the results is theoretically explained by the 
abundance of plasma proteins in each solution, which in turn affects the Zetasizer ZS’s 
correlation function, making the results less accurate. The clear and concise peaks shown 
by the measurements of the Nanosight NS300 can be explained by the use of fluorescent 
filters, which block all scattered light other than that from the fluorescently tagged 
polystyrene nanoparticles. After looking at both the theoretical usages and the measured 
data sets, it is clear that NTA through the Nanosight NS300 is more reliable than DLS 





plasma. For that reason, the Nanosight NS300 was used for the dilution experiments to size 


























PLASMA DILUTION EXPERIMENT 
 
3.1 Methods and Materials 
As discussed in Chapter 2, the Nanosight NS300 provides the most accurate size 
measurements of nanoparticles in blood plasma, and therefore was the primary instrument 
used to do so. Both the solution preparation and the Nanosight NS300 operation were 
previously described in Section 2.2, and no changes were made to either of those 
procedures to carry out the experiments discussed in this section. In addition to measuring 
dilutions 6 through 9, the remaining dilutions were also prepared, measured and analyzed 
using the Nanosight NS300.  
The dilution experiments were carried out on two separate batches of goat blood 
plasma, both ordered from Lampire Biological Laboratories. One of the experiment sets 
was carried out in the Spring of 2016 by Dr. Kathleen McEnnis while the second set was 
carried out in the Summer of 2018 by Mark Bannon. The same exact stock solution of 
polystyrene nanoparticles was used for each of the sets of experiments. The goat blood 
plasma batch used in the set of 2018 experiments will be referred to as “Plasma 2”, while 
the batch used in 2016 will be referred to as “Plasma 1”. To properly analyze the effects of 
the plasma dilutions and eventual protein corona formation on the incubated polystyrene 
particles, a control of measured polystyrene particles in pure saline solution was deemed 
necessary. 
A control solution was created for each of the ten dilutions. Just like the plasma 
dilutions, 10 microliters of polystyrene nanoparticles were incubated using the same exact 





replaced with the same volume of saline solution. After the ten-minute incubation period, 
additional saline (preheated to 37°C) was added to the incubated solution, and the resulting 
suspension was measured by the Nanosight NS300. The Nanosight NS300’s laser, 
temperature and recording settings were identical to those described in Section 2.2. 
 
3.2 Measured Size of Nanoparticles in Blood Plasma 
The measured hydrodynamic diameter of nanoparticles after incubation in the various 
dilutions for each batch of plasma and pure saline can be summarized in Tables C.1 through 
C.5. The information is visually summarized below in Figure 3.1. 
 
Figure 3.1 Plotted Hydrodynamic Diameter of Polystyrene Nanoparticles After 






In addition to graphing the measured hydrodynamic diameter of the nanoparticles, 
fitted equations were created through linear regression. While these fitted lines appear as 
linear equations, they are logarithmic equations. For the exact fitted equations and 
associated R2 values, see Table C.6. Like Figure 2.6, each data point represents the average 
size data calculated from three runs of in between seven and 10 measurements taken with 
each dilution. 
Firstly, it is clear that similar trends exist between each batch of plasma. As the 
solutions become less dilute, the measured size of the nanoparticles in solution increases. 
Next, some overlap can be seen between data points in the two separate batches. This 
suggests that different batches of plasma can produce the same sized nanoparticle protein 
corona for the same dilution, however statistical analysis would be warranted in order to 
be able to conclude this. Statistical analysis should also be done on each dilution in each 
batch of plasma in order to conclude the statistical difference between measured 
nanoparticle hydrodynamic diameters developed in each respective dilution. Finally, both 
the developed slope and the overall similarities in the measured sizes of nanoparticles in 
pure saline solutions lead to the assumption that, in pure saline, the particles’ hydrodynamic 
diameters are statistically similar across each dilution. Once again, this warrants statistical 











STATISTICAL ANALYSIS OF POLYSTYRENE NANOPARTICLE SIZE DATA 
 
4.1 Analysis of Variance 
Statistical significance can be determined between two or more groups of raw data through 
a single factor analysis of variance (ANOVA). This method assesses the amount of 
variance both within and between group means, and then compares the two values together. 
From these variances, several parameters are created for analysis. The sum of squares 
between groups (SSB) represents the variation of group means from the total mean, while 
the mean of squares between groups (MSB) is the SSB divided by the degrees of freedom 
between groups. Vice versa, the sum of squares within groups (SSW) represents the sum 
of squared deviations of the group means and individual observations. Like the MSB, the 
mean of squares within groups (MSW) is equal to the SSW divided by the degrees of 
freedom [11].  
Next, the ratio of the MSB and MSW is determined, which compares between 
group variance and within group variance, generally referred to as F. There is also a pre-
calculated expected value of F, which is called the critical F value. If the F value is greater 
than the critical F value, then there are differences between group means that cannot be 
accounted for by error or chance. Conversely, if the F value is smaller than the critical F 
value then the two sets of data are considered statistically similar, meaning that any 
differences in the datasets can be explained by error [11]. Single Factor ANOVA was 
performed on the two batches of data in Microsoft Excel. First, ANOVA tests were 





statistical significance between dilutions. Next, an ANOVA test was performed on each 
batch of plasma to determine the statistical significance between batches. 
 
4.2 ANOVA Test on Dilutions of Pure Saline 
The single factor ANOVA test on hydrodynamic diameters of polystyrene particles 
measured in pure saline is summarized in Table 4.1.  
Table 4.1 Single Factor ANOVA Summary of Hydrodynamic Diameters of Nanoparticles 
Incubated in 10 Incremental Dilutions of Saline 
SUMMARY      
Groups Count Sum Average Variance   
Dilution 0 25 5111.20 204.45 532.06   
Dilution 1 30 6091.10 203.04 57.57   
Dilution 2 25 5067.40 202.70 72.64   
Dilution 3 30 6173.80 205.79 64.39   
Dilution 4 30 6000.40 200.01 46.53   
Dilution 5 25 5196.40 207.86 152.26   
Dilution 6 30 6014.60 200.49 33.99   
Dilution 7 27 5521.70 204.51 359.30   
Dilution 8 28 5684.30 203.01 76.77   
Dilution 9 30 6057.50 201.92 28.39   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Between Groups 1365.48 9 151.72 1.18 0.31 1.92 
Within Groups 34217.49 267 128.16       
Total 35582.97 276         
 
The calculated F value was 1.18, while the critical F value was 1.92. As the 
calculated F value is less than the critical F value, the measured hydrodynamic diameters 
of nanoparticles measured in pure saline are found to be statistically similar to each other. 





across each dilution in saline, but it also proves that a significant nanoparticle protein 
corona is being measured in plasma. 
The statistical similarity of the measured hydrodynamic diameters proves that the 
variation in procedure between each dilution does not cause a size increase in 
nanoparticles. The only difference between the saline and plasma measurements is the fact 
that plasma is being added to the incubation solution. Because the dilution procedure does 
not cause fluctuation in size, the interactions between plasma and the nanoparticles are 
causing an increase in size. In other words, the Nanosight NS300 is measuring 
nanoparticles with a sizeable protein corona on them when incubated in plasma. 
 
4.3 ANOVA Test Across Dilutions of Plasma Batches 
The single factor ANOVA test on hydrodynamic diameters of polystyrene particles 





Table 4.2 Single Factor ANOVA Summary of Hydrodynamic Diameters of Nanoparticles 
Incubated in 7 Incremental Dilutions of Plasma 1 
 
Unfortunately, raw data was only available for dilutions 0-6 for Plasma 1, the data 
for which is shown in Table 4.6. Here, the F-value of 12.69 is much larger than the critical 
F value of 2.14, showing that the measured hydrodynamic diameters of polystyrene 
nanoparticles incubated in Plasma 1 are statistically different across each dilution. In other 
words, there is a different sized protein corona developed onto the incubated nanoparticles 
for each dilution of Plasma 1.  
The single factor ANOVA test on hydrodynamic diameters of polystyrene particles 





Table 4.3 Single Factor ANOVA Summary of Hydrodynamic Diameters of Nanoparticles 
Incubated in 10 Incremental Dilutions of Plasma 2 
 
Once again, the F-value of 50.54 is much larger than the critical F value of 1.92, 
showing that the measured hydrodynamic diameters of polystyrene nanoparticles 
incubated in Plasma 2 are also statistically different across each dilution. Because of the 
statistical difference displayed across dilutions 0-10 in Tables 4.2 and 4.3, the trends shown 
in Figure 3.1 can be confirmed. As each nanoparticle suspension becomes less dilute with 








4.4 ANOVA Test Across Separate Plasma Batches 
The single factor ANOVA test on the average hydrodynamic diameters of polystyrene 
particles in each dilution measured in Plasma Batch 1 and Plasma Batch 2 is summarized 
in Table 4.4. 
Table 4.4 Single Factor ANOVA Summary of Measured Hydrodynamic Diameters of 
Nanoparticles Incubated in Plasma 1 and Plasma 2  
 
The F-value of 2.26 is obviously smaller than the critical F-value of 4.41, meaning 
that the measured hydrodynamic diameters of nanoparticles in their respective dilutions are 
statistically similar across each batch of plasma. This confirms the visual similarities 
between each set of data in plasma shown in Figure 3.1, and that two batches of plasma 
from the same species will produce similar sized protein coronas. The statistical analysis 
of the hydrodynamic diameters of nanoparticles in each dilution was useful, however it 










AVERAGE PROTEIN CORONA THICKNESS ANALYSIS 
 
5.1 Average Thickness of Developed Protein Coronas 
According to the definition of the protein corona discussed in Chapter 1, the protein 
corona can be thought of as a shell around the nanoparticle in solution. Because the 
Nanosight NS300 assumes that all measured particles are perfectly spherical, that same 
assumption can be applied to a particle’s protein corona. It is important to note that it is 
not guaranteed that every nanoparticle and its resulting corona will be perfectly spherical 
in shape. By subtracting the true measured size of the nanoparticles in saline for each 
dilution from the hydrodynamic diameter of the particle and protein corona and then 
dividing the resultant number in half, the actual thickness of the protein corona was able 
to be determined. This information is summarized in Tables C.7 and C.8 for both batches 
of blood plasma used. 
The thickness ranges in between 20 and 50 nanometers, with standard error that is 
once again very low, ranging from 1 to 5 nm. While these thicknesses seem negligible in 
terms of size, they become very significant when taking the size of the nanoparticles being 
used into account. In terms of percent change, incubation of nanoparticles in blood plasma 
was found to increase the overall nanoparticle diameter from anywhere between 20% and 
50% of its original size. This change is substantial and based upon the trends seen in Figure 
3.1, when a nanoparticle is incubated in undiluted blood plasma in a human body, this 
change could increase even more. The information in Tables C.7 and C.8 is visually 
38 
 
summarized in Figure 5.1  
                                                
Figure 5.1 Average Thickness of Protein Coronas After Incubation in Various Dilutions 
of Blood Plasma and Saline Solution for Plasma 1 and Plasma 2 
 
 Like Figure 3.1, there is a clearly positive trend portrayed by the data. As the plasma 
solutions become less dilute, the resultant protein corona becomes thicker. This makes 
sense, as the protein corona thickness is directly related to the overall hydrodynamic 
diameter of the nanoparticles in incubation. This figure just provides a more streamlined 
way of looking at the data. More detailed information about the logarithmic relationships 






Table 5.1 Fitted Equations Developed from the Linear Regression of the Data Plotted in 
Figure 5.1 
 
Once again, overlap can be seen between thickness data points in the two separate 
batches of plasma. This suggests that different batches of plasma can produce protein 
corona with similar thickness. Based upon the statistical analysis done on the 
hydrodynamic diameters of the incubated nanoparticles between batches of plasma, it is 
assumed that this conclusion is accurate, however more statistical analysis would be 
warranted. Statistical analysis should also be done on each dilution in each batch of plasma 
in order to conclude the difference between protein corona thickness developed in each 
respective dilution of each batch of plasma. Finally, statistical analysis should be 
completed on the linear regression equations in Table 5.1 to determine their statistical 
significance.  
 
5.2 ANOVA Tests on Average Protein Corona Thickness 
The ANOVA test on the average protein corona thickness of nanoparticles incubated in 








Table 5.2 Single Factor ANOVA Summary of Average Protein Corona Thickness of 
Nanoparticles Incubated in 7 Incremental Dilutions of Plasma 1 
 
Once again, raw data was only available for dilutions 0-6 for Plasma 1, the data for 
which is shown in Table C.3. Here, the F-value of 12.94 is much larger than the critical F 
value of 2.14, showing that average protein corona thickness of polystyrene nanoparticles 
incubated in Plasma 1 are statistically different across each dilution. In other words, there 
is a different sized protein corona developed onto the incubated nanoparticles for each 
dilution of Plasma 1. Because the average protein corona thickness is directly related to the 
measured hydrodynamic size of nanoparticles in suspension, this result was expected. 
The ANOVA test on the average protein corona thickness of nanoparticles 







Table 5.3 Single Factor ANOVA Summary of Average Protein Corona Thickness of 
Nanoparticles Incubated in 10 Incremental Dilutions of Plasma 2 
 
The F-value of 50.12 is much larger than the critical F value of 1.92, showing that 
the average protein corona thickness of polystyrene nanoparticles incubated in Plasma 2 
are also statistically different across each dilution. Because of the statistical difference 
displayed across dilutions in Tables 5.2 and 5.3, the trends shown in Figure 5.1 can be 
confirmed. As each nanoparticle suspension becomes less dilute with respect to plasma, 
the average thickness of the protein corona developed onto nanoparticles increases. 
 The ANOVA test on average protein corona thickness of nanoparticles incubated 






Table 5.4 Single Factor ANOVA Summary of Average Protein Corona Thickness of 
Nanoparticles Incubated in Plasma 1 and Plasma 2 
 
The F-value of 2.24 is obviously smaller than the critical F-value of 4.4, meaning 
that the average protein corona thickness of nanoparticles incubated in their respective 
dilutions are statistically similar across each batch of plasma. This confirms the visual 
similarities between each set of data in plasma shown in Figure 3.1, and that two batches 
of plasma from the same species will produce similar sized overall protein coronas. Being 
able to compare overall protein coronas is useful, however, as discussed in Chapter 1, 
protein corona is characterized by both the hard and soft corona. Therefore, it is important 
to be able to differentiate between these two components in these measurements. 
 
5.3 Statistical Analysis of Average Protein Corona Thickness Regression 
Table 5.1 displays the equations of the fitted lines plotted on Figure 5.1, comparing the 
average protein corona thickness to the logarithm of the percentage of plasma present in 
each dilution. The two equations look visually similar on Figure 5.1 and appear to have 





determined that these linear equations could be used to characterize the size of the hard 
and soft protein coronas within each batch of plasma. 
It was determined that the slope of the linear equation determines the effect of the 
soft corona on the overall average protein corona thickness, while the constant of the linear 
equation determines the effect of the hard corona on the overall average protein corona 
thickness. Recalling the definition of protein corona, the hard corona is comprised of one 
layer of proteins that are directly bound to the surface of the nanoparticle. Therefore, it can 
be assumed that compared to the thickness of the overall protein corona, which is around 
50 nanometers, the small thickness of the hard corona will stay fairly constant across the 
protein coronas developed in each dilution. In an equation that determines the overall 
thickness, it should be represented by the unchanging constant. The slope of the equation 
determines the change in the overall thickness of the protein corona, and as the solutions 
become less dilute the thickness increases. Therefore, it can be assumed that the 
nanoparticles incubated in the less dilute solutions have the same sized hard corona but 
have larger soft coronas. Therefore, as the slope accounts for variation between dilutions, 
it therefore represents the size of the soft corona.  
In order to analyze the difference between the hard and soft corona across batches 
of plasma, statistical analysis needed to be performed on the two linear regression 
equations. Statistical analysis of slopes and constants produced through linear regression 
can be completed through hypothesis testing. For both the slopes and the constants, the two 
data sets were separated by a categorical variable, which identified which set of plasma the 





For the developed slopes, a fitted regression was developed for each set of data 
while taking an interaction effect into account. Interaction effects display the effects of 
factors on each dependent measure, or the size/thickness of the particle/protein corona, 
showing that the impact of a factor depends on the level of another factor [12]. In this case, 
the interaction effect is the product of the log of the percentage of plasma in solution and 
the categorical variable, “Plasma Batch”, with “A” representing Plasma 2 and “B’ 
representing Plasma 1. This procedure provides two linear fits with which the developed 
coefficients (or slopes) could be assessed. Figure 5.2 shows an example of the results of a 
hypothesis test on two sets of developed slopes and constants [18]. 
 
Figure 5.2 Minitab Results from a Coefficient Comparison Between Two Independently 
Developed Coefficients Using a Hypothesis Test. 




 A couple of things should be seen in a coefficient table such as above. When 
considering the significance of the slopes, the cell of value is the intersection between 
“Input*Condition”, which is the interaction effect, and P-Value. The hypothesis test starts 
with the hypothesis that the two developed slopes of the linear regressions are equal, which 
would be supported by a P-value of greater than the confidence interval at which this 





Value of the interaction term is 0, which is less than 0.05, and therefore the null hypothesis 
can be rejected, and the two slopes can be considered statistically significant [18]. 
When considering the significance of the constants, the cell of value is the 
intersection between “Condition” and P-Value. The hypothesis test starts with the 
hypothesis that the two developed constants of the linear regressions are equal, which 
would be supported by a P-value greater than the confidence interval at which this analysis 
was ran, which for all intents and purposes will be 0.05. In Figure 5.2, the P-Value of the 
interaction term is 0, which is less than 0.05, and therefore the null hypothesis can be 
rejected, and the two coefficients can be considered statistically significant. These 
principles will now be provided to the previously discussed data [18]. Table 5.5 displays 
the statistical analysis of the linearly regressed equations fit to the average protein corona 
thickness of nanoparticles incubated in Plasma 1 and Plasma 2. 
 
Table 5.5 Regression Analysis of Fitted Equations Developed from the Data Plotted in  
 
Obviously, the P-Value associated with the interaction effect (Plasma 
Concentration*Plasma Batch B) is larger than the confidence interval of 0.05, with a value 





statistical significance between the two slopes produced by the linear regression of the 
average protein corona thickness plotted against the logarithm of the percentage of plasma 
present in each dilution. Because there is no statistical significance between the two slopes 
produced by linear regression of the average protein corona thickness for each plasma 
batch, it can be concluded that the soft corona has the same effect on the overall protein 
corona for different batches of plasma from the same species. In other words, each batch 
of plasma should have similarly sized soft protein coronas. 
The P-Value associated with the Plasma Batch value is smaller than the confidence 
interval of 0.05, with a value of 0.003. This means that the null hypothesis can be rejected, 
and that there is a statistical significance between the two constants produced by the linear 
regression of the average protein corona thickness plotted against the logarithm of the 
percentage of plasma present in each dilution. Because there is a statistical significance 
between the two constants produced by linear regression of the average protein corona 
thickness for each plasma batch, it can be concluded that the hard corona has a different 
effect on the overall protein corona for different batches of plasma from the same species. 














6.1 Dilution Experiment Expansion 
The dilution experiment was an excellent springboard towards understanding protein 
corona composition, however much more work needs to be done to confirm some of the 
discovered trends. In order to determine the validity of future use of the Nanosight NS300, 
experiments will need to be done in which nanoparticles are incubated in undiluted blood 
plasma. This will allow for a more accurate simulation of the interactions between blood 
plasma proteins and nanoparticle drug delivery solutions. As the goal of these experiments 
is to simulate flow of nanoparticle drug systems within the human body, the ability to 
measure the hydrodynamic diameter of nanoparticles in undiluted plasma is crucial to 
future implementation. 
 Different types of blood plasma must be tested in order to confirm the existence of 
the claimed trends across different species. Because human blood plasma is a biohazard 
and requires special engineering controls to safely use, it would be wise to test the claim 
on another animal. Figure 6.1 shows a comparison of the results of zone electrophoresis 













Figure 6.1 Comparison Between Human and Ox Blood Plasma Using Zone 
Electrophoresis. 
Source: Source: Morris, Bede, and F. C. Courtice. “The Protein And Lipid Composition Of The Plasma Of 
Different Animal Species Determined By Zone Electrophoresis And Chemical Analysis.” Quarterly Journal 
of Experimental Physiology and Cognate Medical Sciences, vol. 40, no. 2, 7 Nov. 1955, pp. 127–137., 
doi:10.1113/expphysiol.1955.sp001104. 
 
Like goat blood plasma, bovine plasma is quite similar to human blood plasma. 
Both plasma types contain significant amounts of fibrinogen, gamma, beta and alpha 
globulins and albumin. Zone electrophoresis also migrated the lipids contained in bovine 
plasma into two distinct areas, despite human lipids being migrated into three. However, 
both lipid migrations contained a zone localized around the albumin and beta-globulin 
protein areas [16]. Bovine plasma is safer to use than human blood, and its use will be a 
greater step forward in either confirming or denying some of the trends seen in goat plasma 
across different types of plasma. While the goal still remains to be able to control protein 
corona in human plasma, use of all other plasma types still acts as an intermediary to 





Different nanoparticles with different surface chemistries must be used in future 
experiments. The important of surface charge and various physical characteristics of 
nanoparticle systems in protein corona formation was discussed in Chapter 1, and it 
remains an important task to understand the roles of these traits in protein corona 
development. A commonly used polymer in nanoparticle drug delivery systems is 
poly(lactic-co-glycolic acid), also known as PLGA. Another popular substance used is gold 
nanoparticles, which are often used in cancer remediation because of the inherent stability 
to assembly and malleable surface properties [9]. Another option is changing the surface 
chemistry of the PLGA nanoparticles by using polyethylene glycol, or PEG, which 
theoretically masks nanoparticles from proteins in blood plasma [1]. Not only will varying 
the surface chemistry and types of nanoparticle systems provide more information upon 
nanoparticle and plasma protein interactions, but it could lead towards information on the 
most efficient and useful nanoparticle system. PEGylated particles have already been 
synthesized using 1K, 5K, 10K and 30K PEG, and future experiments will be done on 
those particles in order to determine their influence on the development of the protein 
corona. 
 
6.2 Determining Protein Corona Composition 
To prove the theories discussed from the results of the hypothesis testing, one would have 
to be able to physically distinguish between the hard and soft corona. In Microfluidic 
Examination of the ‘Hard’ Biomolecular Corona Formed on Engineered Particles in 
Different Biological Milieu, Weiss discusses a technique for washing nanoparticles after 





nanoparticles, as it is weakly bound to the particle. However, the proteins that make up the 
hard corona should be able to retain their bonds to the particle. By this logic, one would be 
able to measure the size of only the particle and the hard corona. The sizes of these washed 
particles could then be compared from dilution to dilution, and if the theory holds up, would 
prove that the size of each nanoparticle and hard corona would be constant regardless of 
the amount of blood plasma each nanoparticle is incubated in [23]. Therefore, any 
hydrodynamic diameter variation seen in Figure 3.1 or thickness variation seen in Figure 
5.1 would be a direct result in a change in the size of the soft protein corona. 
Weiss also discusses the possible determination of the composition of the hard 
corona after the washing step through gel electrophoresis and mass spectrometry. Gel 
electrophoresis would allow the proteins present on the hard corona to be separated by 
atomic mass. Mass spectrometry would be able to determine the relative amounts of each 
protein in the hard protein corona [23]. These experiments are extremely important for 
multiple reasons.  
 First, understanding the proteins that make up the protein corona could allow 
different measures to be taken to avoid the binding of those proteins, such as changing 
nanoparticle surface chemistry. Knowing the relative amounts of the proteins present in the 
protein corona will give more information on how the protein corona is formed, and a better 
inherent understanding of the clashing between Vroman’s Effect and Brownian Motion. 
Finally, knowing the composition of individual protein coronas would give information on 
the binding affinities of individual proteins, which would help future design of drug 
delivery nanoparticles and even assist in perfecting the quantification of the effective 





nanoparticle systems as drug delivery solutions, and therefore experiments to determine 
protein corona composition are vital for future research. 
 
6.3 Binding Affinity 
A successive project resulting from this work would be to calculate the binding affinity of 
blood plasma to nanoparticles. According to experiments done by Zhang et al., the binding 
affinity is calculated using calorimetry data from nanoparticle incubation in blood plasma, 
attained using Isothermal Titration Calorimetry. Binding affinities in the literature are 
calculated for individual protein solutions and nanoparticles incubated within them, 
however the goal is to be able to calculate said binding affinities for overall batches of 
plasma containing many different proteins and then comparing the affinities for similarities 
[25].  
 The binding affinity can be calculated from the Gibb’s Free Energy, which can be 
calculated from the enthalpy and entropy measured through calorimetry data. The equation 
for the binding affinity is ∆G = RT × ln (𝑘𝐴), Where ∆G is the Gibb’s Free Energy, R is 
the universal gas constant, T is the absolute temperature and kA is the binding affinity of 
the solvent. By comparing the binding affinities of batches of plasma with those from 
individual protein solutions it is believed that the composition of the protein corona will be 
able to be determined, or at least easier to characterize. A goal is also to measure these 
binding affinities onto different types of nanoparticles, such as the newly developed 










While the experiments and resultant analysis discussed above give updated and useful 
information about protein corona, it is clear that many more experiments will have to be 
carried out before nanoparticle drug delivery systems are efficient. The results of the 
dilution experiment generated some interesting claims and trends, all of which will be 
referred to and implemented in further work. That being said, there is definitely a future 
for nanoparticle drug delivery in pharmaceutical practice. 
 Firstly, NTA is a more reliable method of measuring the hydrodynamic diameter 
of nanoparticles in solutions containing blood plasma. It was made clear that measurements 
from DLS were unreliable and theoretically inaccurate even at dilutions containing a small 
amount of goat blood plasma. The measurements using the Nanosight NS300 appeared 
accurate up to the 35.5% blood plasma solution that has been tested so far, however the 
machine’s fluorescent capabilities should allow for the hydrodynamic diameter of 
nanoparticles to be measured in undiluted blood plasma, which is crucial, as that is what 
nanoparticles will be in when implemented in the body. 
 The dilution experiment proved the existence of protein corona around polystyrene 
nanoparticles upon incubation in blood plasma. The statistical similarity between the 
hydrodynamic diameters of polystyrene nanoparticles across all ten “dilutions” of pure 
saline proved that neither the saline nor the dilution preparation should have any effect on 
the size of the nanoparticles, and all size changes are a result of the interactions between 





the measured diameters of polystyrene nanoparticles across all ten dilutions of plasma in 
each batch prove that each dilution produces a different sized protein corona.   
 After careful statistical analysis using single factor ANOVA, it was determined that 
the both the measured hydrodynamic diameters of and average protein corona thickness 
surrounding each polystyrene nanoparticle were considered statistically similar for both 
batches of goat plasma used. Hypothesis testing on the slopes and constants generated by 
regression showed that while the slopes were statistically similar, the developed constants 
were not. This can be translated in terms of the soft and hard corona, saying that the size 
of the soft corona will stay generally constant and the hard corona will change between 
batches of blood plasma from the same species, specifically goat plasma. In order to 
actually prove this claim, more experiments will have to be done in goat plasma, as a 
sample size of two batches simply is not enough to make any accurate assumptions. 
 Finally, future work must be done in order to ensure the massive potential of 
nanoparticle drug delivery is reached. More experiments must be done using blood plasma 
from different species, different types of nanoparticles, different nanoparticle surface 
charges, and finally using human blood plasma. The composition of developed protein 
coronas can be determined from gel electrophoresis and mass spectrometry, and therefore 
experiments should be designed to determine said composition in order to understand the 
best way to inhibit nanoparticle interactions with specific proteins within the plasma. 
Finally, calorimetry data of the development of a protein corona upon incubation of 
nanoparticles should be collected in order to calculate binding affinities of plasma onto 







Dynamic Light Scattering 
 
A.1 Malvern Zetasizer Nano ZS 
 
 
Figure A.1 Schematic of Malvern Zetasizer Nano ZS 
 
The above schematic shows the operation of the Malvern Zetasizer Nano ZS. A cuvette 
containing a suspension (in this case blood plasma dilutions with polystyrene 
nanoparticles) is placed into the machine and the lid is closed. A laser then shines light 
through the samples, which will then be scattered by any particles that come into contact 
with it. This scattered light is reflected towards a detector, which will send a signal to the 
computer. The result of this system is the measured hydrodynamic diameter of the 








A.2 Dilution Experiment 
Raw data from DLS is in the form of the correlation function, which the software fits to 
produce the size distribution as the intensity of scattered light plotted against the measured 
hydrodynamic diameters of the particles in suspension. The fit to the correlation function 
developed in order to create the size distribution is described by the “Expert Advice” Tab 
in the Zetasizer’s user interface. This tab describes the goodness of fit of the size data, and 
where the sample quality was good enough to produce an accurate function. The DLS 
results for each of the separate runs are displayed in the following figures. 





Figure A.3 Description of Data Quality for Saline, Run #1 
 





Figure A.5 Description of Data Quality for Saline, Run #2 
 
 






Figure A.7 Description of Data Quality for Saline, Run #3 
 
 


















Figure A.11 Description of Data Quality for Dilution 9, Run #2 
 
 






Figure A.13 Description of Data Quality for Dilution 9, Run #3 
 
 






Figure A.15 Description of Data Quality for Dilution 8, Run #1 
 
 






Figure A.17 Description of Data Quality for Dilution 8, Run #2 
 
 






Figure A.19 Description of Data Quality for Dilution 8, Run #3 
 
 






Figure A.21 Description of Data Quality for Dilution 7, Run #1 
 
 






Figure A.23 Description of Data Quality for Dilution 7, Run #2 
 
 






Figure A.25 Description of Data Quality for Dilution 7, Run #3 
 
 






Figure A.27 Description of Data Quality for Dilution 6, Run #1 
 
 






Figure A.29 Description of Data Quality for Dilution 6, Run #2 
 
 






Figure A.31 Description of Data Quality for Dilution 6, Run #3 
 
 The individual data shown in Figures A.2 through A.31 is summarized in Table 
A.1. Averages for each dilution were calculated by averaging the most frequently measured 
nanoparticle hydrodynamic diameter within each dilution, and then displayed in the fifth 













Table A.1 Hydrodynamic Diameters of Polystyrene Particles Incubated in Plasma 2 

























































262.77 36 9.91 1.65 
14.92 4.90 
6.95 0.70 
2 290.40 100.00 
3 253.20 100.00 
Saline 
1 207.90 100.00 
226.30 36 13.13 2.19 2 233.30 100.00 









Due to the required accuracy needed for the Nanosight NS300 to correctly distinguish the 
size of the particles to the nanometer, a Fisherbrand Traceable thermometer was used to 
closely monitor and ensure that the temperature was retained at 37°C. Fourteen milliliters 
of each dilution were prepared and heated to 37°C by means of a water bath. These samples 
were then loaded into a glass Ubbelohde capillary viscometer.  Ten separate measurements 
were taken at 37°C for each dilution. In order to attain the dynamic viscosity of each 
dilution, the measured kinematic viscosity in 
m2
s
 was multiplied by the density of the 
dilution’s density, in 
kg
m3
, in order to get the dynamic viscosity, in 
kg
m×s
. The results attained 













Table B.1 Kinematic Viscosity of Dilutions of Goat Blood Plasma and Saline Converted 



























Dilution 0 0.970 1 0.970 0.003 
Dilution 1 0.841 1 0.841 0.006 
Dilution 2 0.769 1 0.769 0.003 
Dilution 3 0.747 1 0.747 0.005 
Dilution 4 0.732 1 0.732 0.003 
Dilution 5 0.727 1 0.727 0.004 
Dilution 6 0.722 1 0.722 0.001 
Dilution 7 0.736 1 0.736 0.002 
Dilution 8 0.730 1 0.730 0.001 
Dilution 9 0.738 1 0.738 0.003 
 
 
To measure the density of each dilution, a 2mL Eppendorf tube was massed and 
then loaded with either 500, 750, or 1000 μL of one of the ten dilutions. The overall mass 
of the tube and the solution would then be taken, and the mass of the tube would be 
subtracted from the overall mass in order to calculate the final mass of the dilution. The 
mass of the solution would then be divided by the overall volume in order to achieve the 
density in final units of 
kg
m3
. This process was repeated for each dilution, and the standard 





measurements was determined small enough to conclude that the amount of volume used 
to measure did not affect the overall density measurement, and therefore all 30 individual 
measured densities for each dilution were averaged. There was clearly an error in the values 
of the measured dilutions, and the averaged values are included in the Table B.2. 
 













Dilution 0 0.990 0.004 0.001 
Dilution 1 0.978 0.010 0.003 
Dilution 2 0.947 0.023 0.008 
Dilution 3 0.973 0.007 0.002 
Dilution 4 0.966 0.016 0.005 
Dilution 5 0.969 0.004 0.001 
Dilution 6 0.977 0.020 0.007 
Dilution 7 0.972 0.003 0.001 
Dilution 8 0.967 0.009 0.003 
Dilution 9 0.971 0.025 0.008 
  
 
The density of saline solution is 1.0046 
kg
m3
, and human blood plasma can be 
approximated to around 1.0025 
kg
m3
 [7] [21]. By this logic, the density of any dilution of 
blood plasma and saline solution needs to be in between those two values. All the calculated 
average densities were consistently under 1 
kg
m3





of any of the dilutions. This error could have occurred in the actual measurement, although 
the consistency and low standard error in measurements says otherwise. The most likely 
source of error comes from clotting factors within the plasma, such as fibrinogen, 
aggregating within the plasma over time, and affecting the density of the plasma upon 
measurement, as these measurements were done on Plasma 1 well after the earlier 
experiments were completed. 
Because the densities of the two solutions are so close to 1
kg
m3
, substituting the 
measured kinematic viscosity as the dynamic viscosity would produce less error than using 
the measured densities of the blood plasma to convert between the two. As a matter of fact, 
the error within the Nanosight NS300’s individual measurements are larger than the error 
provided with this substitution. Therefore, in order to correctly measure the hydrodynamic 
viscosities of the particles in each dilution, the kinematic viscosity was considered equal 
















NANOPARTICLE TRACKING ANALYSIS 
 
C.1 Malvern Nanosight NS300 
 
Figure C.1 Schematic of Malvern Nanosight NS300 
 
Figure C.1 displays a schematic of the Nanosight NS300. First, a sample is loaded into a 
syringe, which is then connected to a tube that feeds into the Nanosight. The sample is then 
pumped into a microfluidic device sitting on top of a laser module. An objective attached 
to a camera hangs over this viewing plate and has the ability to record the light scattered 
by the particles as the laser sends light through the sample. The data captured by the camera 
is then analyzed, during which each beam of scattered light is analyzed by the Nanosight 
NS300 to calculate the measured hydrodynamic diameter of each particle. A “mode size” 







C.2 Dilution Experiment 
The measurement procedure was repeated with two sets of blood plasma and pure saline, 
and the data is summarized for each run of each dilution in Tables C.1 – C.5. 
 
Table C.1 Hydrodynamic Diameters of Polystyrene Nanoparticles Incubated in Plasma 2 
Dilution # 
Percent of 











Dilution 0 100 297.98 22 9.63 2.05 
Dilution 1 50 303.11 24 7.70 1.57 
Dilution 2 25 269.54 24 58.17 11.87 
Dilution 3 12.5 283.33 27 11.95 2.30 
Dilution 4 6.25 275.32 20 8.57 1.92 
Dilution 5 3.125 277.64 30 11.12 2.03 
Dilution 6 1.5625 270.91 26 7.35 1.44 
Dilution 7 0.78125 263.12 21 4.64 1.01 
Dilution 8 0.390625 262.55 23 4.81 1.00 





Table C.2 Raw Data Used to Calculate the Hydrodynamic Diameters of Polystyrene 



















Table C.3 Hydrodynamic Diameters of Polystyrene Particles Incubated in Plasma 1 
Dilution # 
Percent of 












Dilution 0 100 294.73 42 21.78 3.36 
Dilution 1 50 286.74 42 32.33 4.99 
Dilution 2 25 284.34 35 21.41 3.62 
Dilution 3 12.5 272.04 28 8.28 1.56 
Dilution 4 6.25 272.23 25 12.76 2.55 
Dilution 5 3.125 263.35 28 15.92 3.01 
Dilution 6 1.5625 266.35 49 11.30 1.61 
Dilution 7 0.78125 253.75 30 7.18 1.31 
Dilution 8 0.390625 253.32 29 7.71 4.32 






Table C.4 Hydrodynamic Diameters of Polystyrene Particles Incubated in Saline Solution 
Dilution # 
Percent of 












Dilution 0 100 204.45 25 24.34 4.87 
Dilution 1 50 203.04 30 7.59 1.39 
Dilution 2 25 202.69 25 8.52 1.70 
Dilution 3 12.5 205.79 30 8.02 1.47 
Dilution 4 6.25 200.01 30 6.82 1.25 
Dilution 5 3.125 207.86 25 12.34 2.47 
Dilution 6 1.5625 200.49 30 5.83 1.06 
Dilution 7 0.78125 204.51 27 18.96 3.65 
Dilution 8 0.390625 203.01 28 8.76 1.66 

















Table C.5 Raw Data Used to Calculate Hydrodynamic Diameters of Polystyrene Particles 
Incubated in Saline Solution 
 
 
Table C.6 Fitted Equations Relating Hydrodynamic Diameter with Percentage of Plasma 
in Dilution 
Data Set Equation R2 
Plasma 2 
Y = 14.21 × log10(X) + 276.41 0.79 
Plasma 1 
Y = 14.89 × log10(X) + 265.82 0.90 
Saline 
Y = 0.58 × log10(X) + 202.35 0.06 
 
Tables C.7 and C.8 display the measured protein corona thickness in each dilution. 




















Dilution 0 45.14 25.12 3.02 22.08% 0.07 
Dilution 1 41.85 33.12 4.21 20.61% 0.08 
Dilution 2 40.82 23.04 2.97 20.14% 0.06 
Dilution 3 33.13 11.53 1.51 16.10% 0.04 
Dilution 4 36.11 15.07 2.03 18.05% 0.04 
Dilution 5 28.03 17.32 2.38 13.49% 0.07 
Dilution 6 32.93 16.73 1.88 16.43% 0.04 
Dilution 7 24.62 9.250 1.23 12.04% 0.08 
Dilution 8 25.15 20.46 2.71 12.39% 0.04 



























48.24 4.86 1.04 23.60% 0.09 
Dilution 1 
53.41 3.94 0.8 26.31% 0.03 
Dilution 2 
47.13 5.07 1.06 23.25% 0.04 
Dilution 3 
42.76 6.14 1.18 20.78% 0.04 
Dilution 4 
42.45 4.43 0.99 21.22% 0.03 
Dilution 5 
39.38 5.74 1.05 18.95% 0.05 
Dilution 6 
42.23 3.86 0.76 21.06% 0.03 
Dilution 7 
33.08 2.39 0.52 16.18% 0.07 
Dilution 8 
34.99 2.5 0.52 17.24% 0.04 
Dilution 9 
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